In tumor subgroup, CCND3 predicted lower OS in breast cancer (HR = 1.64, 95% CI: 1.07‐2.52, P = 0.909), while no significant association was found in other cancers (HR = 1.22, 95% CI: 0.71‐2.09, P < 0.001) (Figure 5C). Here, CCND3 is linked to breast carcinoma.